

# Memory Disorders

[View the current Memory Disorders InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Memory_Disorders.html) (PDF)

([http://www.bioportfolio.com/indepth/Memory\\_Disorders.html](http://www.bioportfolio.com/indepth/Memory_Disorders.html)) - Regularly Updated.



## Recent Publications on Memory Disorders:

- [Behavioral and psychological symptoms associated with dementia subtype and severity.](#)  
*ABSTRACT*Background: There is a growing body of research exploring...13th November, 2009  
Academic Department for Old Age Psychiatry, Prince of Wales Hospital,- Int Psychogeriatr. 2009 Nov 12:1-6. ([DOI Direct Link](#))
- [Alteration of theta timescale dynamics of hippocampal place cells by a cannabinoid is associated with memory impairment.](#)  
*The integrity of the hippocampus is critical for both spatial navigation...*11th November, 2009  
Center for Molecular and Behavioral Neuroscience, Rutgers, The State- J Neurosci. 2009 Oct 7;29(40):12597-605. ([DOI Direct Link](#))
- [Protein Kinase C Activators as Synaptogenic and Memory Therapeutics.](#)  
*The last decade has witnessed a rapid progress in understanding of the...*10th November, 2009  
Blanchette Rockefeller Neurosciences Institute, Rockville, MD, USA. Fax:- Arch Pharm (Weinheim). 2009 Nov 6. ([DOI Direct Link](#))
- [The patient's experience of memory change after elective temporal lobe resection.](#)  
*Subjective memory has emerged as a relevant indicator of outcome following...*3rd November, 2009  
Department of Psychology, Queen Elizabeth II Health Sciences Centre,- Can J Neurol Sci. 2009 Aug;36 Suppl 2:S46-50.
- ["I can't remember": memory deficits in children with epilepsy.](#)  
*Compared with the literature on epilepsy in adults, there is relatively...*3rd November, 2009  
Department of Psychology, University of Toronto Mississauga and The- Can J Neurol Sci. 2009 Aug;36 Suppl 2:S42-5.
- [Epilepsy and memory dysfunction.](#)  
*Compared with the literature on epilepsy in adults, there is relatively...*3rd November, 2009  
- Can J Neurol Sci. 2009 Aug;36 Suppl 2:S41.
- [Origins, Controversies and Recent Developments of the MCI Construct.](#)  
*The MCI construct aims to investigate the grey area existing between...*29th October, 2009  
Neuropsychology Service, Policlinico Gemelli, Catholic University of Rome,- Curr Alzheimer Res. 2009 Sep 28.
- [Retrieval-induced forgetting in normal ageing.](#)  
*The retrieval-induced forgetting (RIF) paradigm was used to assess the...*29th October, 2009  
Department of Cognitive Sciences, University of Liege, Liege, Belgium.- J Neuropsychol. 2008 Sep;2(Pt 2):463-76.
- [Self-Reported Cognitive Inconsistency in Older Adults.](#)

- Insight into one's own cognitive abilities, or metacognition, has been...*24th October, 2009  
University of Victoria, Victoria, British Columbia, Canada.- Neuropsychol Dev Cogn B Aging  
Neuropsychol Cogn. 2009 Oct 21:1-21. ([DOI Direct Link](#))
- [Functional MRI assessment of task-induced deactivation of the default mode network in Alzheimer's disease and at-risk older individuals.](#)  
*Alzheimer's disease (AD) is the most common form of dementia in old age,...*23rd October, 2009  
Memory Disorders Unit, Department of Neurology, Brigham and Women's- Behav Neurol.  
2009;21(1):77-91. ([DOI Direct Link](#))
  - [Large-scale functional brain network abnormalities in Alzheimer's disease: insights from functional neuroimaging.](#)  
*Functional MRI (fMRI) studies of mild cognitive impairment (MCI) and...*23rd October, 2009  
Department of Neurology, Harvard Medical School, Boston, MA, USA.- Behav Neurol.  
2009;21(1):63-75. ([DOI Direct Link](#))
  - [Verbal and spatial learning after temporal lobe excisions in children: An adaptation of the Grober and Buschke procedure.](#)  
*Using an adaptation of Grober and Buschke's procedure, we assessed verbal...*20th October, 2009  
Laboratoire de Psychologie et Neurosciences Cognitives (UMR CNRS 8189),- Epilepsy Behav. 2009  
Nov;16(3):534-8. ([DOI Direct Link](#))
  - [Selective suppression of hippocampal ripples impairs spatial memory.](#)  
*Sharp wave-ripple (SPW-R) complexes in the hippocampus-entorhinal cortex...*14th October, 2009  
Laboratoire de Physiologie de la Perception et de l'Action, College de- Nat Neurosci. 2009  
Oct;12(10):1222-3. Epub 2009 Sep 13. ([DOI Direct Link](#))
  - [Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide.](#)  
*Pharmacological enhancement of hippocampal neurogenesis is a therapeutic...*22nd September, 2009  
Department of Neurochemistry, New York State Institute for Basic Research- Neurobiol Aging. 2009  
Sep 18. ([DOI Direct Link](#))
  - [The effect of alcohol and tobacco consumption, and apolipoprotein E genotype, on the age of onset in Alzheimer's disease.](#)  
*OBJECTIVE: This study examined the association between a history of heavy...*15th September, 2009  
David Geffen School of Medicine at UCLA, Semel Institute for Neuroscience- Int J Geriatr Psychiatry.  
2009 Sep 14. ([DOI Direct Link](#))

## BioNews Results for Memory Disorders

- [Pfizer and Medivation Initiate Two Phase 3 Trials of Dimebon](#)  
*World Pharma News: Nov 6 2009 5:59AM Matching: memory disorders*
- [Pfizer, Medivation begin 2 phase-3 trial of drug dimebon in Alzheimer's disease](#)  
*PharmaBiz: Nov 5 2009 8:04AM Matching: memory disorders*
- [Pfizer And Medivation Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease](#)  
*Pharmaceutical Online: Nov 5 2009 5:45AM Matching: memory disorders*
- [Pfizer And Medivation start two Phase III studies of dimebon in Alzheimer's disease patients](#)  
*Pharmacy Choice: Nov 4 2009 4:01PM Matching: memory disorders*
- [Pfizer And Medivation start two Phase III studies of dimebon in Alzheimer's disease patients](#)  
*Therapeutics Daily: Nov 4 2009 2:56PM Matching: memory disorders*
- [Pfizer And Medivation Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe Alzheimer s Disease](#)  
*SmartBrief: Nov 4 2009 8:13AM Matching: memory disorders*

- [Pfizer and Medivation initiate dimebon trials in patients with Alzheimers disease](#)  
*News-Medical.Net: Nov 4 2009 5:37AM Matching: memory disorders*
- [Pfizer And Medivation Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe Alzheimer's D](#)  
*Pharma Live: Nov 3 2009 8:05PM Matching: memory disorders*
- [Pfizer And Medivation Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe Alzheimers Disease](#)  
*Yahoo! Canada: Nov 3 2009 4:40PM Matching: memory disorders*
- [Pfizer Inc : Pfizer And Medivation Initi](#)  
*Investigate: Nov 3 2009 2:45PM Matching: memory disorders*
- [Pfizer And Medivation Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe Alzheimers](#)  
*Genetic Engineering News: Nov 3 2009 1:57PM Matching: memory disorders*
- [Pfizer And Medivation Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe AlzheimerEUR](#)  
*PR inside: Nov 3 2009 1:38PM Matching: memory disorders*
- [Pfizer And Medivation Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe AlzheimerEUR](#)  
*Business Wire: Nov 3 2009 1:13PM Matching: memory disorders*
- [University Hospitals Case Medical Center to test gammaglobulin treatment for Alzheimer's disease](#)  
*Pharmacy Choice: Oct 14 2009 1:46PM Matching: memory disorders*
- [10 Warning Signs of Alzheimers Disease](#)  
*HealthNewsDigest.com: Oct 12 2009 8:05PM Matching: memory disorders*

#### Memory Disorders Clinical Trials:



- [Evaluation of Age- and Alzheimer's Disease-Related Memory Disorder](#)

#### Memory Disorders Patents:



- 7544684- [Hydrazono-malonitriles](#)
- 7572787- [Substituted naphthalene sulfonamides](#)
- 7572792- [Azetidine glycine transporter inhibitors](#)
- 7572796- [Substituted indoles](#)
- 7572819- [Compounds which potentiate glutamate receptor and uses thereof in medicine](#)
- 7572834- [Rasagiline formulations and processes for their preparation](#)
- 7576081- [Morpholine dopamine agonists](#)

- 7576083- [Morpholinyl piperidine glycine transporter inhibitors](#)
- 7576095- [Therapeutic agents](#)
- 7576103- [Tetralin and indane derivatives and uses thereof](#)
- 7582315- [Composition and method to augment and sustain neurotransmitter production](#)
- 7566735- [Compounds which potentiate AMPA receptor and uses thereof in medicine](#)
- 7566715- [Substituted sulfonamide compounds useful for the prophylaxis and treatment of conditions relating to obesity, type II diabetes and/or disorders of the central nervous system](#)
- 7566709- [1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders](#)
- 7547687- [Therapeutic treatment methods](#)
- 7547699- [Tetracyclic 6 azapyrazinoindolines as 5HT2C receptor agonists for obesity](#)
- 7553828- [9-aminomethyl substituted minocycline compounds](#)
- 7553862- [4-amino-1,5-substituted-1,5-dihydro-imidazol-2-ones](#)
- 7553965- [5-HT.sub.7 receptor antagonists](#)
- 7556938- [Nucleic acids encoding potassium channel interactors](#)
- 7557114- [Heterocyclic-substituted phenyl methanones](#)
- 7563790- [Pyridazine derivatives](#)
- 7563797- [Substituted imidazo\(1,2-A\)pyrimidines and imidazo\(1,2-A\) pyridines as cannabinoid receptor ligands](#)
- 7563821- [Levodopa prodrug mesylate, compositions thereof, and uses thereof](#)
- 7582760- [Benzimidazolone and dihydroindolone derivatives and uses thereof](#)
- 7582767- [Substituted sulphonamide compound and uses thereof](#)
- 7598049- [Methods for diagnosis of Alzheimer's Disease in blood samples](#)
- 7598420- [Rasagiline formulations and processes for their preparation](#)
- 7601369- [Composition and method to augment and sustain neurotransmitter production](#)
- 7601837- [Quinoline derivatives and their use as 5-HT6 ligands](#)
- 7603174- [Stimulation of the amygdalohippocampal complex to treat neurological conditions](#)
- 7605163- [Benzoyl-piperazine derivatives](#)
- 7605176- [.beta.-ketoamide compounds with MCH antagonistic activity](#)
- 7608718- [4,5-dihydro-1H-pyrazole derivatives having potent CB.sub.1-antagonistic activity](#)
- 7611857- [IL-receptor like molecules and uses thereof](#)
- 7611858- [Detection of cannabinoid receptor biomarkers and uses thereof](#)
- 7595314- [Benzoyl-piperazine derivatives](#)
- 7595159- [Prediction of Parkinson's disease using gene expression levels of peripheral blood samples](#)
- 7595067- [Composition and method to augment and sustain neurotransmitter production](#)
- 7582797- [Derivatives of 4,4'-dithiobis-\(3-aminobutane-1-sulfonates\) and compositions comprising the same](#)
- 7585517- [Transscleral delivery](#)
- 7585523- [Composition and method to augment and sustain neurotransmitter production](#)
- 7585996- [Acyloxyalkyl carbamate prodrugs, methods of synthesis and use](#)
- 7589089- [Inhibitors for GlyT-1](#)
- 7589120- [N-\[\(4,5-diphenyl-2-thienyl\)methyl\]sulfonamide derivatives, preparation thereof and their therapeutic application](#)
- 7589206- [Pyrrolopyridine derivatives](#)
- 7592346- [Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors](#)
- 7592358- [Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds](#)
- 7592373- [Amide compounds with MCH antagonistic activity and medicaments comprising these compounds](#)
- 7611879- [27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

